Novocure

Yahoo Finance • 2 days ago

NovoCure Q4 Earnings Call Highlights

NovoCure logo NovoCure (NASDAQ:NVCR) reported record fourth-quarter and full-year 2025 revenue on its latest earnings call, while outlining regulatory, clinical and commercial milestones expected in 2026, including the recent FDA approval... Full story

Yahoo Finance • 15 days ago

Soleus Adds a Significant Number of Celcuity Shares

Key Points Soleus increased its Celcuity stake by 629,398 shares. The firm held over 1.8 million shares at the end of the quarter. Celcuity now accounts for 6.7% of fund AUM10 stocks we like better than Celcuity › On Feb. 12, Soleus Capi... Full story

Yahoo Finance • 15 days ago

Sector Update: Health Care Stocks Rise Late Afternoon

Health care stocks were higher late Thursday afternoon, with the NYSE Health Care Index adding 0.8% PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • 15 days ago

Sector Update: Health Care Stocks Higher Thursday Afternoon

Health care stocks edged higher Thursday afternoon, with the NYSE Health Care Index adding 0.1% and PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • 2 months ago

Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference

BAAR, Switzerland, December 22, 2025--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that management will participate in the 44th Annual J.P. Morgan Healthcare Conference taking place in San Francisco on January 12-15, 2026. Fran... Full story

Yahoo Finance • 3 months ago

Stock Market Today: Nasdaq, S&P 500 Open Higher to Start Week; Novo Nordisk Plummets After Ozempic Alzheimer's Miss

This live blog is refreshed periodically throughout the day with the latest updates from the market.To find the latest Stock Market Today threads, click here. Happy Monday. This is TheStreet’s Stock Market Today for Nov. 24, 2025. You can... Full story

Yahoo Finance • 4 months ago

2 Healthcare Stocks for Individual Investors With a 40-Year Time Horizon

Key Points A biotech upstart and a life sciences giant could be compelling additions to an investor's portfolio. NovoCure is a high-risk but potentially high-reward bet on industry-changing technology. Danaher has faced some headwinds to... Full story

Yahoo Finance • 4 months ago

Novocure outlines four-indication expansion and profitability target for 2027 as GBM growth continues

Earnings Call Insights: Novocure Limited (NVCR) Q3 2025 MANAGEMENT VIEW * Executive Chairman William Doyle stated that Novocure is transitioning from a single indication company to a platform therapy company, with a focus on "preparing... Full story

Yahoo Finance • 4 months ago

NovoCure GAAP EPS of -$0.33 beats by $0.09, revenue of $167M beats by $8.06M

* NovoCure press release [https://seekingalpha.com/pr/20285935-novocure-reports-third-quarter-2025-financial-results] (NVCR [https://seekingalpha.com/symbol/NVCR]): Q3 GAAP EPS of -$0.33 beats by $0.09. * Revenue of $167M (+7.7% Y/Y) b... Full story

Yahoo Finance • 7 months ago

Form 13G NovoCure Ltd. For: 13 August

... Full story

Yahoo Finance • 7 months ago

Leerink Partners Reiterates a Buy Rating on NovoCure Limited (NVCR)

NovoCure Limited (NASDAQ:NVCR) is one of the best medical device stocks to buy according to analysts. Leerink Partners analyst Jonathan Chang reiterated a Buy rating on NovoCure Limited (NASDAQ:NVCR) on July 24, setting a price target of $... Full story

Yahoo Finance • 7 months ago

Novocure stock hits 52-week low at 10.88 USD

Novocure Ltd (NASDAQ:NVCR) stock has reached a new 52-week low, closing at 10.88 USD. The medical technology company, with a market capitalization of $1.22 billion, has seen its shares decline 62.65% year-to-date. According to InvestingPr... Full story

Yahoo Finance • 7 months ago

Strategic Education Becomes Oversold

The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important characteristics — strong fundamentals a... Full story

Yahoo Finance • 7 months ago

NovoCure GAAP EPS of -$0.36 beats by $0.03, revenue of $158.8M beats by $4.6M

* NovoCure press release [https://seekingalpha.com/pr/20176390-novocure-reports-second-quarter-2025-financial-results] (NASDAQ:NVCR [https://seekingalpha.com/symbol/NVCR]): Q2 GAAP EPS of -$0.36 beats by $0.03. * Revenue of $158.8M (+5... Full story

Yahoo Finance • 8 months ago

NovoCure stock initiated with Buy rating at Ladenburg Thalmann

Investing.com - Ladenburg Thalmann initiated coverage on NovoCure Ltd. (NASDAQ:NVCR) with a Buy rating and a $30.00 price target on Tuesday. According to InvestingPro data, this target aligns with the broader analyst consensus, as the stoc... Full story

Yahoo Finance • 8 months ago

NovoCure stock maintains Buy rating at H.C. Wainwright on positive cancer trial data

Investing.com - H.C. Wainwright has reiterated a Buy rating and $38.00 price target on NovoCure Ltd. (NASDAQ:NVCR) following positive trial results for its cancer treatment. Currently trading at $17.88, the stock shows potential upside acc... Full story

Yahoo Finance • 8 months ago

Novocure to Report Second Quarter 2025 Financial Results

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) will report financial results for the second quarter 2025 on July 24, 2025, before the U.S. financial markets open. Novocure management will host a conference call and webcast at... Full story

Yahoo Finance • 9 months ago

The Next Frontier to Treat Cancer: Electricity

Scientists are testing electric fields and pulses against a range of diseases including rheumatoid arthritis and brain cancer. Continue Reading View Comments... Full story

Yahoo Finance • last year

FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer

The first treatment of its kind for metastatic NSCLC, Optune Lua is approved for use concurrently with PD-1/PD-L1 inhibitors or docetaxel in adult patients with metastatic NSCLC who progressed on or after a platinum-based regimen Results... Full story

Yahoo Finance • 2 years ago

Novocure to Report Second Quarter 2024 Financial Results

ROOT, Switzerland, July 01, 2024--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2024 on Thursday, July 25, 2024, before the U.S. financial markets open. Novocure manag... Full story